Kei Namba

950 total citations
41 papers, 668 citations indexed

About

Kei Namba is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Kei Namba has authored 41 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 20 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Kei Namba's work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Kei Namba is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (8 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Kei Namba collaborates with scholars based in Japan, United States and Canada. Kei Namba's co-authors include M. Kubo, Hiromasa Yamamoto, Shinichi Toyooka, Junichi Soh, Kazuhiko Shien, Shuta Tomida, Hidejiro Torigoe, Hiroki Sato, T. Tani and Yoshiyuki Kimura and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Kei Namba

41 papers receiving 650 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kei Namba Japan 15 333 251 215 107 95 41 668
Edward Licitra United States 8 400 1.2× 221 0.9× 203 0.9× 171 1.6× 70 0.7× 13 838
Liangliang Bai China 17 348 1.0× 251 1.0× 141 0.7× 156 1.5× 57 0.6× 51 838
Daniele G. Soares France 14 439 1.3× 277 1.1× 103 0.5× 143 1.3× 65 0.7× 29 820
Weixi Shen China 14 181 0.5× 155 0.6× 138 0.6× 89 0.8× 38 0.4× 28 580
Dhanvanthri S. Deevi United States 12 429 1.3× 289 1.2× 117 0.5× 74 0.7× 34 0.4× 18 884
Alex Starr Israel 16 532 1.6× 350 1.4× 100 0.5× 111 1.0× 83 0.9× 25 936
Wenbin Song China 19 540 1.6× 245 1.0× 204 0.9× 213 2.0× 44 0.5× 36 985
Nengming Lin China 19 569 1.7× 221 0.9× 180 0.8× 173 1.6× 45 0.5× 55 870
Martin Wurm Austria 12 364 1.1× 233 0.9× 67 0.3× 85 0.8× 88 0.9× 20 861
Yingqiu Zhang China 15 487 1.5× 225 0.9× 78 0.4× 139 1.3× 48 0.5× 31 772

Countries citing papers authored by Kei Namba

Since Specialization
Citations

This map shows the geographic impact of Kei Namba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Namba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Namba more than expected).

Fields of papers citing papers by Kei Namba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kei Namba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Namba. The network helps show where Kei Namba may publish in the future.

Co-authorship network of co-authors of Kei Namba

This figure shows the co-authorship network connecting the top 25 collaborators of Kei Namba. A scholar is included among the top collaborators of Kei Namba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kei Namba. Kei Namba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tanaka, Atsushi, Makiko Ogawa, Yihua Zhou, et al.. (2024). Proteogenomic characterization of primary colorectal cancer and metastatic progression identifies proteome-based subtypes and signatures. Cell Reports. 43(2). 113810–113810. 14 indexed citations
2.
Ogawa, Makiko, Atsushi Tanaka, Kei Namba, et al.. (2022). Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer. Scientific Reports. 12(1). 2767–2767. 8 indexed citations
3.
Namba, Kei, Kazuhiko Shien, Akihiro Miura, et al.. (2022). One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective study. Scientific Reports. 12(1). 7297–7297. 4 indexed citations
4.
Yamamoto, Hiromasa, Junichi Soh, Etsuji Suzuki, et al.. (2020). A Simple Prognostic Benefit Scoring System for Sarcoma Patients with Pulmonary Metastases: Sarcoma Lung Metastasis Score. Annals of Surgical Oncology. 28(7). 3884–3890. 7 indexed citations
5.
Soh, Junichi, Seiichiro Sugimoto, Kei Namba, et al.. (2020). Chronic Lung Injury After Trimodality Therapy for Locally Advanced Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery. 112(1). 279–288. 4 indexed citations
6.
Yamamoto, Hiromasa, Kei Namba, Junichi Soh, et al.. (2020). The neutrophil-to-lymphocyte ratio as a novel independent prognostic factor for multiple metastatic lung tumors from various sarcomas. Surgery Today. 51(1). 127–135. 10 indexed citations
7.
Yamamoto, Hiromasa, Ken Suzawa, Shuta Tomida, et al.. (2019). YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers. Cancer Science. 111(3). 849–856. 17 indexed citations
8.
Kurihara, Eisuke, Kazuhiko Shien, Hidejiro Torigoe, et al.. (2019). Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research. 39(4). 1767–1775. 8 indexed citations
9.
Shien, Kazuhiko, Kota Araki, Akihiro Miura, et al.. (2019). P1.03-16 Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation. Journal of Thoracic Oncology. 14(10). S423–S424. 2 indexed citations
10.
Yoshioka, Takahiro, Kazuhiko Shien, Yuta Takahashi, et al.. (2019). Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells. Cancer Science. 110(8). 2549–2557. 30 indexed citations
11.
Namba, Kei, Kazuhiko Shien, Yuta Takahashi, et al.. (2018). Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 17(2). 499–507. 71 indexed citations
12.
Torigoe, Hidejiro, Kazuhiko Shien, Takahiro Yoshioka, et al.. (2018). Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations. Cancer Science. 109(5). 1493–1502. 20 indexed citations
13.
Sato, Hiroki, Masakiyo Sakaguchi, Hiromasa Yamamoto, et al.. (2018). Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. Oncogenesis. 7(1). 11–11. 9 indexed citations
14.
Yamamoto, Hiromasa, Hirotaka Kanzaki, Ken Suzawa, et al.. (2017). Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE. 12(2). e0171356–e0171356. 29 indexed citations
15.
Shien, Kazuhiko, Hiroki Sato, Ken Suzawa, et al.. (2017). P3.02b-121 Targeting miR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-Small Cell Lung Cancer Cells Harboring EMT Features. Journal of Thoracic Oncology. 12(1). S1267–S1267. 1 indexed citations
16.
Torigoe, Hidejiro, Junichi Soh, Shuta Tomida, et al.. (2017). Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. Journal of Thoracic Disease. 9(9). 3076–3086. 4 indexed citations
17.
Chen, Haiyang, Kazuhiko Shien, Ken Suzawa, et al.. (2017). Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncology Letters. 14(4). 4349–4354. 22 indexed citations
18.
Ohtsuka, Tomoaki, Masakiyo Sakaguchi, Hiromasa Yamamoto, et al.. (2016). Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Scientific Reports. 6(1). 39557–39557. 22 indexed citations
19.
20.
Kubo, M., et al.. (1983). A New Phenolic Glucoside, Curculigoside from Rhizomes of Curculigo orchioides. Planta Medica. 47(1). 52–55. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward Licitra Breakdown of academic impact, for papers by Liangliang Bai Breakdown of academic impact, for papers by Daniele G. Soares Breakdown of academic impact, for papers by Weixi Shen Breakdown of academic impact, for papers by Dhanvanthri S. Deevi Breakdown of academic impact, for papers by Alex Starr Breakdown of academic impact, for papers by Wenbin Song Breakdown of academic impact, for papers by Nengming Lin Breakdown of academic impact, for papers by Martin Wurm Breakdown of academic impact, for papers by Yingqiu Zhang
Rankless by CCL
2026